Vidipha Central Pharmaceutical Faces Financial Challenges Amid Rising Costs and Interest Expenses

Vidipha Central Pharmaceutical JSC has recently undergone an evaluation adjustment, reflecting changes in its underlying financial metrics and market position. The company, operating within the Pharmaceuticals & Biotechnology sector, has reported flat financial performance for the quarter ending September 2025. Notably, the return on capital employed (ROCE) has been recorded at 8.37%, which is among the lowest levels observed. Additionally, the company has experienced a significant increase in interest expenses, which rose by 26.15%, amounting to VND 3,135.14 million. The cost of raw materials has also seen a substantial year-over-year growth of 45.94%, indicating rising operational costs that may impact profitability. Despite these challenges, Vidipha Central Pharmaceutical JSC has maintained a return on equity (ROE) of 9.08%, suggesting a fair valuation with a price-to-book ratio of 0.00. Over the past year, the stock has generated a return of 39.47%, while profits have seen a marginal increase of 0.1%. These factors contribute to the recent revision in its evaluation, highlighting the complexities of its current financial landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.